Drug intelligence / Profile preview

telmisartan + chlorthalidone

Development stage
Unknown
Lead developer
Boehringer Ingelheim
Modality
Small Molecules
Administration
Oral
01

Overview

This is a fixed-dose combination drug containing **telmisartan**, an angiotensin II receptor blocker (ARB), and **chlorthalidone**, a thiazide-like diuretic. **Telmisartan** works by selectively blocking the binding of angiotensin II to the AT1 receptor, resulting in vasodilation and reduced blood pressure. **Chlorthalidone** increases urinary excretion of sodium and chloride, leading to decreased fluid volume and blood pressure. The combination is indicated for the treatment of hypertension, particularly in patients not controlled with monotherapy, and is also used in chronic kidney disease and diabetic nephropathy. Typical oral formulations are used in clinical practice. Clinical studies demonstrate efficacy in lowering blood pressure in patients uncontrolled by either agent alone or combinations with hydrochlorothiazide[1][2][4].

Brand names
TELMITRUST CT
Other names
Telovia CTTelmisartan + Chlorthalidone
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on telmisartan + chlorthalidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on telmisartan + chlorthalidone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call